VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-2.91%)
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
VivoSim Labs cash
Cash and short-term investments held at the end of each period.
VivoSim Labs's cash was $1.67M at Jun 30, 2026. For fiscal 2026 it was $5.02M, down 55.6% from the year before. Over ten years it grew -22.2% a year on average. The highest annual figure on record is $62.75M in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $5.02M | -55.6% |
| FY2025 | Mar 31, 2025 | $11.31M | +289.9% |
| FY2024 | Mar 31, 2024 | $2.90M | -81.0% |
| FY2023 | Mar 31, 2023 | $15.30M | -46.6% |
| FY2022 | Mar 31, 2022 | $28.68M | -23.3% |
| FY2021 | Mar 31, 2021 | $37.36M | +36.6% |
| FY2020 | Mar 31, 2020 | $27.36M | -25.0% |
| FY2019 | Mar 31, 2019 | $36.48M | -16.6% |
| FY2018 | Mar 31, 2018 | $43.73M | -30.3% |
| FY2017 | Mar 31, 2017 | $62.75M | +1.1% |
| FY2016 | Mar 31, 2016 | $62.09M | +23.8% |
| FY2015 | Mar 31, 2015 | $50.14M | +238.4% |
| FY2012 | Dec 31, 2012 | $14.82M | +4257.9% |
| FY2011 | Dec 31, 2011 | $340.00K | +19.3% |
| FY2010 | Dec 31, 2010 | $285.00K | +102.1% |
| FY2009 | Dec 31, 2009 | $141.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.67M | -81.6% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $5.02M | -55.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $4.29M | +269.3% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $6.68M | +110.4% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $9.06M | +46.4% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $11.31M | +289.9% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.16M | -78.1% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $3.17M | -58.3% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $6.19M | -42.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $2.90M | -81.0% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $5.30M | -73.8% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $7.62M | -67.2% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $10.75M | -57.8% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $15.30M | -46.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $20.20M | -33.3% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $23.22M | -31.3% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $25.47M | -29.3% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $28.68M | -23.3% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $30.27M | +60.7% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $33.79M | +91.4% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $36.01M | +45.3% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $37.36M | +36.6% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $18.84M | -38.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $17.66M | -41.8% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $24.79M | -30.2% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $27.36M | -25.0% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $30.47M | -13.5% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $30.35M | -18.8% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $35.49M | -10.4% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $36.48M | -16.6% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $35.22M | -25.6% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $37.36M | -26.4% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $39.61M | -27.9% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $43.73M | -30.3% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $47.34M | -32.4% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $50.73M | -1.9% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $54.97M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $62.75M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $70.00M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $51.72M | – |
See a number that looks wrong?